Clinical Trial Detail

NCT ID NCT02627443
Title Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

Therapies

Carboplatin + Gemcitabine

Berzosertib

Age Groups: adult

No variant requirements are available.